

PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING**I****OBSERVE MEDICAL ASA**
ORGANISASJONSNUMMER 822 907 822

Den 22. november 2023 kl. 09.00 ble det avholdt ekstraordinær generalforsamling i Observe Medical ASA ("**Selskapet**"), på Selskapets kontorer i Dronning Eufemias gate 16, 0191 Oslo, Norge.

Generalforsamlingen ble åpnet av styrets leder, Terje Bakken, som opptok fortegnelse over møtende aksjeeiere, herunder de aksjeeierne som var representert på generalforsamlingen ved fullmakt. Fortegnelsen, inkludert antall aksjer og stemmer representert, er inntatt som Vedlegg 1 til protokollen.

I henhold til fortegnelsen var 23 879 761 av totalt 53 491 656 utstedte aksjer og stemmer, som tilsvarer 44,64 % av det totale antall stemmeberettigede aksjer i Selskapet, representert på generalforsamlingen.

Følgende saker ble behandlet:

1 VALG AV MØTELEDER

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Terje Bakken velges til å lede generalforsamlingen.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

2 VALG AV ÉN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN SAMMEN MED MØTELEDEREN

Generalforsamlingen valgte Per Arne Nygård til å medundertege protokollen sammen med møtelederen.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

3 GODKJENNING AV INNKALLING OG DAGSORDEN

Møteleder opplyste om at innkalling og dagsorden til generalforsamlingen hadde blitt sendt til samtlige aksjeeiere med kjent oppholdssted den 1. november 2023.

*(OFFICE TRANSLATION)***MINUTES OF EXTRAORDINARY GENERAL MEETING****OF****OBSERVE MEDICAL ASA**
COMPANY REGISTRATION NUMBER 822 907 822

An extraordinary general meeting of Observe Medical ASA (the "**Company**") was held on 22 November 2023 at 09:00 hours (CET), at the Company's offices at Dronning Eufemias gate 16, 0191 Oslo, Norway.

The general meeting was opened by the chairperson of the board of directors, Terje Bakken, who kept a record of attending shareholders, including the shareholders attending by proxy. The record of attending shareholders, including the number of shares and votes represented, is attached to these minutes as Appendix 1.

According to the record, 23,879,761 of a total of 53,491,656 issued shares and votes, corresponding to 44.64% of the total number of voting shares in the Company, were represented at the general meeting.

The following matters were discussed:

1 ELECTION OF A PERSON TO CHAIR THE MEETING

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

Terje Bakken is elected to chair the meeting.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES TOGETHER WITH THE CHAIR OF THE MEETING

The general meeting elected Per Arne Nygård to co-sign the minutes together with the chairperson of the meeting.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

3 APPROVAL OF THE NOTICE AND THE AGENDA

The chairperson of the meeting informed the general meeting that the notice and the agenda had been sent to all shareholders with known address on 1 November 2023.

I samsvar med styrets forslag traff generalforsamlingen følgende vedtak:

Innkallingen og dagsorden sendt til samtlige aksjeeiere med kjent adresse den 1. november 2023, godkjennes.

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

Møtelederen erklærte generalforsamlingen som lovlig satt.

4 KAPITALFORHØYELSE I FORBINDELSE MED FORTRINNSRETTSEMISJON

4.1 Bakgrunn

Det ble vist til innkallingen datert 1. november 2023 hvor styret foreslo at generalforsamlingen skal beslutte å forhøye selskapets aksjekapital gjennom en fortrinnsrettsemisjonen for å hente et bruttoproveny på minimum NOK 18 000 000.20 og maksimum NOK 54 999 999,89 ("**Fortrinnsrettsemisjonen**").

Som opplyst i innkallingen har Selskapet mottatt lån fra sine største aksjonærer angitt i Vedlegg 3 ("**Långiverne**") pålydende totalt NOK 16,75 millioner, med tillegg av påløpte renter og renter som vil påløpe til og med det avtalte forfallstidspunktet, som nærmere angitt i Vedlegg 3 ("**Lånene**").

Lånene (inkludert påløpte og uopptjente renter beregnet frem til og med det avtalte forfallstidspunktet) kan benyttes helt eller delvis til motregning mot tegningsbeløpet for nye aksjer i Fortrinnsrettsemisjonen. Det er imidlertid en forutsetning for at Långiverne skal kunne motregne Lånene i Fortrinnsrettsemisjonen at Selskapet henter et bruttoproveny på minimum NOK 18,000,000,20 i kontanter gjennom Fortrinnsrettsemisjonen.

Videre er det en betingelse for gjennomføring av Fortrinnsrettsemisjonen at hver av Långiverne konverterer Lånene fullt ut og/eller inngår en endringsavtale om forlengelse av forfallsdato og til betingelser som er markedsmessige for det gjenværende beløpet i hvert av de respektive Lånene som ikke konverteres.

Generalforsamlingen gikk så over til å behandle styrets forslag om vedtak for aksjekapitalforhøyelse. I samsvar med styrets forslag, herunder styrets forslag til tegningskursen til de nye aksjene som skal utstedes i Fortrinnsrettsemisjonen, og således det endelige antallet nye aksjer og den eksakte størrelsen på aksjekapitalforhøyelsen som ble annonsert gjennom Oslo Børs sin informasjonstjeneste på www.newsweb.no (under

In accordance with the board of directors' proposal, the general meeting passed the following resolution:

The notice and the agenda which were sent to all shareholders with a known address on 1 November 2023, are approved.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

The chairperson of the meeting declared the general meeting as lawfully convened.

4 SHARE CAPITAL INCREASE IN CONNECTION WITH A RIGHTS ISSUE

4.1 Background

Reference was made to the notice dated 1 November 2023, where the board proposed that the general meeting should resolve to increase the Company's share capital, by way of a rights issue, to raise gross proceeds of minimum NOK 18,000,000.20 and maximum NOK 54,999,999.89 (the "**Rights Issue**").

As stated in the notice, the Company has received loans from its largest shareholders listed in Appendix 3 ("**Lenders**") with an aggregate nominal value of NOK 16.75 million, in addition to accrued interest and interest that will accrue up to and including the agreed maturity date, as listed in Appendix 4 (the "**Loans**").

The Loans (including accrued and unaccrued interest calculated up to and including the agreed maturity date), may be utilized fully or partly to set-off against the subscription amount for new shares in the Rights Issue. However, it is a condition for the Lenders to be permitted to convert the Loans in the Rights Issue that the Company raises gross proceeds in cash of a minimum of NOK 18,000,000.20.

Further, it is a condition for completion of the Rights Issue that each of the Lenders convert the Loans in whole and/or enter into an amendment agreement for the remaining amount under each of the respective Loans that are not converted regarding extension of the maturity date and amendment of the terms to market terms.

The general meeting then proceeded to discuss the board of directors' proposal for a resolution regarding the increase of the Company's share capital. In accordance with the board of directors' proposal, including the board of directors' proposal for the subscription price for the new shares to be issued in the Rights Issue, and thus the final number of new shares and the exact amount of the share capital increase as announced through the Oslo Stock Exchange's information system on www.newsweb.no (under the Company's ticker "OBSRV") on 21 November 2023, the

selskapets ticker "OBSRV") den 21. November 2023, ble det fattet følgende vedtak om å forhøye Selskapets aksjekapital:

- (i) Aksjekapitalen forhøyes med minimum NOK 18 000 000,20 og maksimum NOK 54 999 999,86 ved utstedelse av minimum 69 230 770 og maksimum 211 538 461 nye aksjer, hver pålydende NOK 0,26 ("**Fortrinnsrettsemisjonen**").
- (ii) Tegningskursen er NOK 0.26 per aksje.
- (iii) Aksjeeiere i Selskapet per utløpet av 22. november 2023 slik det fremgår av Selskapets aksjeeierregister i Euronext Securities Oslo ("**ESO**") den 24. november 2023 ("**Record Date**") (jf. ESO' to-dagers oppgjørsperiode), skal ha fortrinnsrett til å tegne og bli tildelt de nye aksjene i samme forhold som de eier aksjer i Selskapet, jf. allmennaksjeloven § 10-4 (1).
- (iv) Aksjeeierne angitt i Vedlegg 3 har rett til å gjøre opp aksjeinnskuddet for aksjene ved motregning av lån pålydende totalt NOK 16,75 millioner (med tillegg av påløpte og uopptjente renter beregnet frem til og med det avtalte forfallstidspunktet) som nærmere angitt i Vedlegg 4 ("**Lånene**"). For nærmere beskrivelse av tingsinnskuddet vises det til den uavhengige sakkyndige redegjørelsen inntatt som Vedlegg 3 til innkallingen.
- (v) Omsettelige tegningsrettigheter vil bli utstedt og tegningsrettene skal bli registrert i ESO. Tegningsrettene vil kunne omsettes fra og med første dag i tegningsperioden og frem til kl. 16.30 fire handelsdager før tegningsperiodens slutt. Overtegning og tegning uten tegningsrettigheter er tillatt.
- (vi) I forbindelse med fortrinnsrettsemisjonen vil Selskapet utarbeide et prospekt som skal godkjennes av Finanstilsynet. Med mindre styret beslutter noe annet, skal prospektet ikke registreres hos, eller godkjennes av, noen utenlandsk prospektmyndighet. De nye aksjene kan ikke tegnes av investorer i USA eller i andre jurisdiksjoner der slik tegning ikke er tillatt eller aksjer ikke lovlig kan tilbys til vedkommende uten et prospekt eller tilsvarende dokumentasjon. Selskapet, eller noen som er utnevnt eller instruert av Selskapet, har rett (men ingen plikt) til, for aksjeeiere som er bosatt i USA eller etter Selskapets oppfatning ikke har rett til å tegne nye aksjer på grunn av begrensninger fastsatt i lov eller andre bestemmelser i jurisdiksjonen hvor aksjeeieren er bosatt eller statsborger, å

following resolution to increase the Company's share capital was passed:

- (i) The share capital is increased with minimum NOK 18,000,000.20 and maximum NOK 54,999,999.86 by the issuance of minimum 69,230,770 and maximum 211,538,461 new shares, each with a nominal value of NOK 0.26 (the "**Rights Issue**").
- (ii) The subscription price is NOK 0.26 per share.
- (iii) Shareholders of the Company as of 22 November 2023 as registered as such in the Company's shareholders' register in Euronext Securities Oslo (the "**ESO**") on 24 November 2023 (the "**Record Date**") (cf. the two days' settlement procedure of the ESO) shall have a preferential right to subscribe for and be allocated the new shares in proportion to their shareholding in the Company, cf. Section 10-4 (1) of the Norwegian Public Limited Companies Act.
- (iv) The shareholders listed in Appendix 3 have a right to settle the share contribution for the shares by set-off against the loans with an aggregate nominal value of NOK 16.75 million (in addition to accrued and unpaid interest calculated up to and including the agreed maturity date) as specified in Appendix 4 (the "**Loans**"). For further details on the contribution-in-kind, reference is made to the independent expert report attached to the notice as Appendix 3.
- (v) Tradeable subscription rights will be issued and the subscription rights shall be registered in the ESO. The subscription rights shall be tradeable from and including the first day of the subscription period and until 16:30 (CET) four trading days prior to the end of the subscription period. Over-subscription and subscription without subscription rights is permitted.
- (vi) The Company shall prepare a prospectus in connection with the rights issue, which shall be approved by the Norwegian Financial Supervisory Authority. Unless the board of directors decides otherwise, the prospectus shall not be registered with or approved by any foreign prospectus authority. The new shares may not be subscribed for by an investor resident in the U.S. or in other jurisdictions where such subscription is not permitted or to whom the new shares cannot lawfully be offered without a prospectus or similar documentation. The Company, or anyone appointed or instructed by the Company, shall have the right to (but no obligation), for shareholders who resides in the U.S. or in the Company's opinion are not entitled to subscribe for new shares due to limitations set out in law or other regulations in the jurisdiction where such shareholder is

selge den aktuelle aksjeeierens tegningsretter mot overføring av netto proventy fra salget til aksjeeieren.

(vii) Tegningsperioden starter den 28. november 2023 og avsluttes kl. 16:30 den 12. desember 2023. Dersom prospektet ikke blir godkjent i tide til å opprettholde denne tegningsperioden, begynner tegningsperioden å løpe på den andre handelsdagen på Euronext Expand etter godkjenning, og avsluttes kl. 16:30 to uker senere. Tegningsperioden kan ikke forkortes, men styret kan forlenge tegningsperioden dersom dette er påkrevd ved lov som følge av offentliggjøring av tillegg til prospektet.

(viii) Tegningsbeløpet skal betales kontant eller ved motregning av Lånene. Det er en betingelse for gjennomføring av Fortrinnsrettsemisjonen at (i) Selskapet klarer å hente bruttoproventy i Fortrinnsrettsemisjonen på minimum NOK 18 000 000,20 i kontanter og (ii) at hver av Långiverne konverterer Lånene fullt ut og/eller inngår en endringsavtale om forlengelse av forfallsdato og til betingelser som er markedsmessige for det gjenværende beløpet i hvert av de respektive Lånene som ikke konverteres. Betaling for de nye aksjene skal skje senest innen 15. desember 2023, eller innen den fjerde handelsdagen på Euronext Expand etter tegningsperiodens utløp dersom tegningsperioden utsettes i henhold til avsnitt (vi) eller (vii) ovenfor. Tegnere som har en norsk bankkonto må, og vil ved å signere tegningsblanketten, gi en ugjenkallelig engangsfullmakt til å belaste en spesifisert norsk bankkonto for beløpet som skal betales for aksjene som blir tildelt tegneren. Beløpet trekkes fra den angitte bankkontoen på eller rundt betalingsdagen. Tegnere som ikke har norsk bankkonto, må sørge for at betaling for de nye aksjene som tildeles dem skjer slik at betalingen mottas på eller før betalingsdagen.

(ix) De nye aksjene tildeles av styret. Følgende tildelingskriterier skal gjelde:

(a) Tildeling av aksjer til tegnere vil bli foretatt i henhold til tildelte og ervervede tegningsrettigheter som er gyldig utøvd i tegningsperioden. Hver tegningsrett vil gi rett til å tegne og bli tildelt én (1) ny aksje i fortrinnsrettsemisjonen.

(b) Dersom ikke alle tegningsretter er gyldig utøvd i tegningsperioden, vil tegnere som har benyttet seg av sine tegningsrettigheter og som har overtegnet, bli tildelt flere nye aksjer på pro rata-basis basert på det antall tegningsrettigheter som er utøvd av hver tegner. I den

resident or a citizen, sell the relevant shareholder's subscription rights against transfer of the net proceeds from such sale to the shareholder.

(vii) The subscription period shall commence on 28 November 2023 and expire at 16:30 (CET) on 12 December 2023. If the prospectus is not approved in time to uphold this subscription period, the subscription period shall commence on the second trading day on Euronext Expand following the approval and expire at 16:30 hours (CET) two weeks thereafter. The subscription period may not be shortened, but the board of directors may extend the subscription period if this is required by law due to the publication of a supplement prospectus.

(viii) The subscription amount shall be paid in cash or by way of set-off against the Loans. It is a condition for completion of the Rights Issue that (i) the Company raising gross proceeds in the Rights Issue of minimum NOK 18,000,000.20 in cash and (ii) that each of the Lenders convert the Loans in whole and/or enter into an amendment agreement for the remaining amount under each of the respective Loans that are not converted regarding extension of the maturity date and amendment of the terms to market terms. Payment for the new shares shall be made on or prior to 15 December 2023, or the fourth trading day on Euronext Expand after the expiry of the subscription period if the subscription period is postponed according to subparagraph (vi) or (vii) above. Subscribers who have a Norwegian bank account must, and will by signing the subscription form, give a one-time irrevocable authorisation to debit a specified Norwegian bank account for the amount payable for the shares which are allocated to the subscriber. The amount will be debited from the specified bank account on or around the payment date. Subscribers who do not have a Norwegian bank account must ensure that payment with cleared funds for the new shares allocated to them is received on or before the payment date.

(ix) The new shares shall be allocated by the board of directors. The following allocation criteria shall apply:

(a) Allocation of shares to subscribers will be made in accordance with granted and acquired subscription rights which have been validly exercised during the subscription period. Each subscription right will give the right to subscribe and be allocated one (1) new share in the rights issue.

(b) If not all subscription rights are validly exercised during the subscription period, subscribers who have exercised their subscription rights and over-subscribed, will be allocated additional new shares on a pro rata basis based on the number of subscription rights exercised by each subscriber.

utstrekning pro rata tildeling ikke er mulig vil Selskapet bestemme tildelingen ved loddtrekning.

(c) Nye aksjer som ikke er tildelt i henhold til punkt (ix) a) til (b) ovenfor, vil bli tildelt tegnere som ikke eier tegningsretter. Tildeling vil bli søkt gjennomført på pro rata basis basert på deres respektive tegningsbeløp.

(x) De nye aksjene gir fulle aksjeeierrettigheter i Selskapet, herunder rett til utbytte, fra og med tidspunktet for registrering av kapitalforhøyelsen i Foretaksregisteret.

(xi) Selskapets vedtekter § 4 endres til å reflektere den nye aksjekapitalen og det nye antall aksjer etter kapitalforhøyelsen.

(xii) Kostnadene som skal betales av Selskapet ved kapitalforhøyelsen er foreløpig anslått til å være mellom NOK 3 900 000 og NOK 5 100 000 (avhengig av det endelige tegningsbeløpet i Fortrinnsrettsemisjonen).

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

* * *

Mer forelå ikke til behandling og generalforsamlingen ble hevet.

* * *

To the extent that pro rata allocation is not possible, the Company will determine the allocation by drawing of lots.

(c) New shares not allocated pursuant to item (ix) a) to (b) above, will be allocated to subscribers not holding subscription rights. Allocation will be sought made on a pro rata basis based on their respective subscription amounts.

(x) The new shares will carry full rights in the Company, including the right to dividend, from the time of the registration of the share capital increase with the Norwegian Register of Business Enterprises.

(xi) Section 4 of the Company's articles of association will be amended to reflect the new share capital and the new number of shares following the share capital increase.

(xii) The costs payable by the Company in connection with the share capital increase are for the time being estimated to be between NOK 3,900,000 and NOK 5,100,000 (depending on the final subscription amount in the Rights Issue).

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

* * *

There were no further matters to be discussed and the general meeting was adjourned.

* * *

22. november 2023 / 22 November 2023

DocuSigned by:

Terje Bakken
4319669DCF1D48D...

Terje Bakken
Møteleder / Chairperson

Vedlegg:

1. Fortegnelsen over møtende aksjeeiere, inkludert antall aksjer og stemmer representert
2. Stemmeresultater
3. Oversikt over Långiverne og Lånene

DocuSigned by:

Per Arne Nygård
509249379330489...

Per Arne Nygård
Medundertegner / Co-signer

Appendices:

1. Record of attending shareholders, including the number of shares and votes represented
2. Voting results
3. Overview of the Lenders and the Loans

Vedlegg 1 / Appendix 1

Fortegnelsen over møtende aksjeeiere, inkludert antall aksjer og stemmer representert / Record of attending shareholders, including the number of shares and votes represented

Totalt representert



ISIN: NO0010865009 OBSERVE MEDICAL ASA
Generalforsamlingsdato: 22.11.2023 09.00
Dagens dato: 22.11.2023

Antall stemmeberettigede personer representert/oppmøtt : 1

	Antall aksjer	% kapital
Total aksjer	53 491 656	
- selskapets egne aksjer	0	
Totalt stemmeberettiget aksjer	53 491 656	
Representert ved forhåndsstemme	3 110 407	5,82 %
Sum Egne aksjer	3 110 407	5,82 %
Representert ved fullmakt	15 958 659	29,83 %
Representert ved stemmeinstruks	4 810 695	8,99 %
Sum fullmakter	20 769 354	38,83 %
Totalt representert stemmeberettiget	23 879 761	44,64 %
Totalt representert av AK	23 879 761	44,64 %

Kontofører for selskapet:

DNB Bank ASA

For selskapet:

OBSERVE MEDICAL ASA

DocuSigned by:

4319669DCF1D48D...



Total Represented

ISIN: N00010865009 OBSERVE MEDICAL ASA
 General meeting date: 22/11/2023 09.00
 Today: 22.11.2023

Number of persons with voting rights represented/attended : 1

	Number of shares	% sc
Total shares	53,491,656	
- own shares of the company	0	
Total shares with voting rights	53,491,656	
Represented by advance vote	3,110,407	5.82 %
Sum own shares	3,110,407	5.82 %
Represented by proxy	15,958,659	29.83 %
Represented by voting instruction	4,810,695	8.99 %
Sum proxy shares	20,769,354	38.83 %
Total represented with voting rights	23,879,761	44.64 %
Total represented by share capital	23,879,761	44.64 %

Registrar for the company:

DNB Bank ASA

Signature company:

OBSERVE MEDICAL ASA

DocuSigned by:

4319669DCF1D48D...

Representertliste OBSERVE MEDICAL ASA 22.11.2023

Firma-/Etternavn	Fornavn	Repr. ved	Beholdning	% av AK
INGERO REITEN INVESTMENT COMPANY A			9 653 680	18,05 %
NAVAMEDIC ASA			4 222 727	7,89 %
RO	LARS		3 058 807	5,72 %
JPB AS			2 830 209	5,29 %
ELI AS			1 744 260	3,26 %
SOLEGLAD INVEST AS			586 668	1,10 %
TRANBERGKOLLEN INVEST AS			500 000	0,94 %
GINNY INVEST AS			500 000	0,94 %
PETTERSEN	GUNERIUS		292 443	0,56 %
GUNERIUS PETTERSEN AS			200 000	0,37 %
HALVORSEN	HALLVARD RUSTAD		160 000	0,30 %
SEED CAPITAL AS			64 067	0,12 %
LINNINGSVOLL	ANDREAS		30 000	0,06 %
WALLE	ANDRÉ		20 000	0,04 %
GJEVRE	KETIL		7 250	0,01 %
BJERKESET	KJETIL		6 500	0,01 %
CHRISTIANSEN	RUNE		1 600	0,00 %

- 1 -

Firma-/Etternavn	Fornavn	Repr. ved	Beholdning	% av AK
GAARDER	ØIVIND TORGEIR BRACHEL		1 300	0,00 %
HEFTE	ARVID		220	0,00 %
TVEDT-GUNDERSEN	AMUND		30	0,00 %

Vedlegg 2 / Appendix 2

Stemmeresultater / Voting results

Protokoll for generalforsamling OBSERVE MEDICAL ASA



ISIN: NO0010865009 OBSERVE MEDICAL ASA
 Generalforsamlingsdato: 22.11.2023 09.00
 Dagens dato: 22.11.2023

Aksjeklasse	For	Mot	Avgitte	Avstår	Ikke avgitt	Stemmeberettigede representerte aksjer
Sak 1 VALG AV MØTELEDER						
Ordinær	20 820 954	3 058 807	23 879 761	0	0	23 879 761
% avgitte stemmer	87,19 %	12,81 %		0,00 %		
% representert AK	87,19 %	12,81 %	100,00 %	0,00 %	0,00 %	
% total AK	38,92 %	5,72 %	44,64 %	0,00 %	0,00 %	
Totalt	20 820 954	3 058 807	23 879 761	0	0	23 879 761
Sak 2 VALG AV ÉN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN SAMMEN MED MØTELEDEREN, SOM FORESLÅS PÅ GENERALFORSAMLINGEN						
Ordinær	20 820 954	3 058 807	23 879 761	0	0	23 879 761
% avgitte stemmer	87,19 %	12,81 %		0,00 %		
% representert AK	87,19 %	12,81 %	100,00 %	0,00 %	0,00 %	
% total AK	38,92 %	5,72 %	44,64 %	0,00 %	0,00 %	
Totalt	20 820 954	3 058 807	23 879 761	0	0	23 879 761
Sak 3 GODKJENNING AV INNKALLING OG DAGSORDEN						
Ordinær	20 820 954	3 058 807	23 879 761	0	0	23 879 761
% avgitte stemmer	87,19 %	12,81 %		0,00 %		
% representert AK	87,19 %	12,81 %	100,00 %	0,00 %	0,00 %	
% total AK	38,92 %	5,72 %	44,64 %	0,00 %	0,00 %	
Totalt	20 820 954	3 058 807	23 879 761	0	0	23 879 761
Sak 4.2 Forslag til vedtak om kapitalforhøyelse						
Ordinær	20 820 954	3 058 807	23 879 761	0	0	23 879 761
% avgitte stemmer	87,19 %	12,81 %		0,00 %		
% representert AK	87,19 %	12,81 %	100,00 %	0,00 %	0,00 %	
% total AK	38,92 %	5,72 %	44,64 %	0,00 %	0,00 %	
Totalt	20 820 954	3 058 807	23 879 761	0	0	23 879 761

Kontofører for selskapet:

DNB Bank ASA

For selskapet:

OBSERVE MEDICAL ASA

DocuSigned by:

4349669DCF4D48D...

Protocol for general meeting OBSERVE MEDICAL ASA

ISIN: N00010865009 OBSERVE MEDICAL ASA
 General meeting date: 22/11/2023 09.00
 Today: 22.11.2023

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 1 ELECTION OF A PERSON TO CHAIR THE MEETING						
Ordinær	20,820,954	3,058,807	23,879,761	0	0	23,879,761
votes cast in %	87.19 %	12.81 %		0.00 %		
representation of sc in %	87.19 %	12.81 %	100.00 %	0.00 %	0.00 %	
total sc in %	38.92 %	5.72 %	44.64 %	0.00 %	0.00 %	
Total	20,820,954	3,058,807	23,879,761	0	0	23,879,761
Agenda item 2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES TOGETHER WITH THE CHAIR OF THE MEETING, TO BE PROPOSED AT THE GENERAL MEETING						
Ordinær	20,820,954	3,058,807	23,879,761	0	0	23,879,761
votes cast in %	87.19 %	12.81 %		0.00 %		
representation of sc in %	87.19 %	12.81 %	100.00 %	0.00 %	0.00 %	
total sc in %	38.92 %	5.72 %	44.64 %	0.00 %	0.00 %	
Total	20,820,954	3,058,807	23,879,761	0	0	23,879,761
Agenda item 3 APPROVAL OF THE NOTICE AND THE AGENDA						
Ordinær	20,820,954	3,058,807	23,879,761	0	0	23,879,761
votes cast in %	87.19 %	12.81 %		0.00 %		
representation of sc in %	87.19 %	12.81 %	100.00 %	0.00 %	0.00 %	
total sc in %	38.92 %	5.72 %	44.64 %	0.00 %	0.00 %	
Total	20,820,954	3,058,807	23,879,761	0	0	23,879,761
Agenda item 4.2 Proposal for the resolution to increase the share capital						
Ordinær	20,820,954	3,058,807	23,879,761	0	0	23,879,761
votes cast in %	87.19 %	12.81 %		0.00 %		
representation of sc in %	87.19 %	12.81 %	100.00 %	0.00 %	0.00 %	
total sc in %	38.92 %	5.72 %	44.64 %	0.00 %	0.00 %	
Total	20,820,954	3,058,807	23,879,761	0	0	23,879,761

Registrar for the company:

DNB Bank ASA



Signature company:

OBSERVE MEDICAL ASA

DocuSigned by:



4319669DCF1D48D...

Vedlegg 3 / Appendix 3**Oversikt over Långiverne og Lånene / Overview of the Lenders and the Loans**

Aksjonær / shareholder	Org.nr. / reg. no.	Adresse / Address	Pålydende / nominal value	Totalt motregningsbeløp inkl. renter / total set-off amount including interests
Navamedic ASA	985012059	Henrik Ibsens gate 100, 0255 Oslo	5 000 000	6 040 825
Ingerø Reiten Investment Company AS	964233713	Haakon VII's gate 1, 0161 Oslo	6 000 000	7 209 997
JPB AS	923311513	Nøkken 26, 9016 Tromsø	2 500 000	3 012 031
ELI AS	917257329	Vestregata 33, 9008 Tromsø	2 000 000	2 409 950
Skålvold Eiendom AS	977248876	Dronningens gate 22, 8514 Narvik	250 000	301 593
Kubera AS	984114540	Teknologiveien 11, 8517 Narvik	250 000	301 893
Harding Invest AS	887580642	Peder Ankers vei 7, 0861 Oslo	250 000	302 021
MP Pensjon PK	938465606	Lakkegata 23, 0187 Oslo	500 000	607 432
Sum			16 750 000	20 185 742

Certificate Of Completion

Envelope Id: FC053336FAA14521AA0BC23581DB0B49 Status: Completed
 Subject: Complete with DocuSign: Observe Medical ASA - Minutes Extraordinary General Meeting 22 November...
 Source Envelope:
 Document Pages: 13 Signatures: 6 Envelope Originator:
 Certificate Pages: 5 Initials: 0 Per Arne Nygård
 AutoNav: Enabled perarne.nygard@observemedical.com
 Envelopeld Stamping: Enabled IP Address: 84.208.98.59
 Time Zone: (UTC-08:00) Pacific Time (US & Canada)


Record Tracking

Status: Original Holder: Per Arne Nygård Location: DocuSign
 11/22/2023 12:59:58 AM perarne.nygard@observemedical.com

Signer Events

Per Arne Nygård
 perarne.nygard@observemedical.com
 CFO
 Observe Medical
 Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

 Per Arne Nygård
 509249379330489...
 Signature Adoption: Drawn on Device
 Using IP Address: 84.208.98.59

Timestamp

Sent: 11/22/2023 1:03:18 AM
 Viewed: 11/22/2023 1:03:29 AM
 Signed: 11/22/2023 1:03:39 AM

Electronic Record and Signature Disclosure:
 Not Offered via DocuSign

Terje Bakken
 tb@reitenco.no
 Chairman
 Security Level: Email, Account Authentication (None)

DocuSigned by:

 Terje Bakken
 4319669DCF1D48D...
 Signature Adoption: Pre-selected Style
 Using IP Address: 188.95.247.249

Sent: 11/22/2023 1:03:17 AM
 Viewed: 11/22/2023 1:10:08 AM
 Signed: 11/22/2023 1:24:14 AM

Electronic Record and Signature Disclosure:
 Accepted: 11/22/2023 1:10:08 AM
 ID: f9b249c0-8637-463a-a30e-7050df52234b

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	11/22/2023 1:03:18 AM
Certified Delivered	Security Checked	11/22/2023 1:10:08 AM
Signing Complete	Security Checked	11/22/2023 1:24:14 AM
Completed	Security Checked	11/22/2023 1:24:14 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Observe Medical ASA (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Observe Medical ASA:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: perarne.nygard@observemedical.com

To advise Observe Medical ASA of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at perarne.nygard@observemedical.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Observe Medical ASA

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to perarne.nygard@observemedical.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Observe Medical ASA

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to perarne.nygard@observemedical.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Observe Medical ASA as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Observe Medical ASA during the course of your relationship with Observe Medical ASA.